Albumedix Ltd

Albumedix logo

Albumedix improves patient outcome with a range of albumin-based products and technologies that facilitate the development of superior biotherapeutics.

Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Our products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide. With over 25 years' experience in the biopharmaceutical industry, we have the scientific, technical and regulatory expertise needed to support companies in moving faster to market with superior biotherapeutics. We also use this expertise to strengthen our own drug pipeline. Albumedix is a global company and a fully owned subsidiary of Novozymes A/S.

Contact Albumedix via their website


News Archive

17/10/2017   Albumedix Establishes Scientific Advisory Board...more
02/10/2017   Albumedix signs agreement with Oslo University Hospital and University of Oslo...more

17/05/2017   Albumedix will host a webinar titled: When Standard Formulation Strategies Fail...more
04/01/2017   Albumedix CEO will present a corporate overview at J.P. Morgan conference...more
04/01/2017   Albumedix Appoints Chief Medical Officer...more

19/12/2016   Nature Communications: Albumedix and collaborators publish new data...more
06/12/2016   Albumedix announce research agreement with New York University (NYU) School of Medicine...more
17/05/2016   Albumedix Agreement with Hebei Changshan Biochem Pharma for Diabetes Treatment...more
12/05/2016   Albumedix™ Proprietary VELTIS® Drug Delivery Technology Approved In The EU...more
15/03/2016   Albumedix Technology used by CSL Behring for Haemophilia B in the US ...more
16/02/2016   Albumedix Announces Exclusive Commercialization Agreement with ThioLogics...more
28/01/2016   Eleven Biotherapeutics and Albumedix Announce Agreement...more

19/01/2015   Novozymes separates its biopharma activities to form independent company...more
19/05/2015   Serendex Pharmaceuticals to initiate trials with Novozymes Biopharma stabilizer...more

22/12/2014   Novozymes Biopharma enters license agreement with EpiVax...more
11/12/2014   Novozymes Biopharma published in Expert Opinion on Drug Delivery...more
05/11/2014   Novozymes Biopharma signs Chinese distribution agreement ...more
29/05/2014   Novozymes Biopharma enters new research agreement with top vaccine company...more
12/05/2014   Novozymes Biopharma announces new collaboration with ThioLogics...more
24/04/2014   Novozymes’ half-life extension technology reaches landmark milestone...more
31/03/2014   Novozymes Biopharma technology used by GlaxoSmithKline in type 2 diabetes drug...more
13/03/2014   Novozymes Biopharma announces collaboration with Janssen...more
21/01/2014   Novozymes Biopharma announces new data on extending serum albumin half-life...more

23/10/2013   Novozymes Biopharma announces collaboration with Almac ...more
18/07/2013   Novozymes Biopharma announce new findings concerning the effect of Hyaluronic Acid...more
29/05/2013   Novozymes Biopharma to showcase world leading products at CPhI China...more
20/05/2013   Novozymes Biopharma helps innovative dry eye therapy move into clinical trials...more
27/02/2013   Novozymes Biopharma's rAlbumin approved in Japan...more
13/02/2013   Novozymes Biopharma announces research agreement with EpiVax...more

21/12/2012   Novozymes aligns recombinant human albumin portfolio with new brand name...more
18/05/2012   Novozymes Biopharma Innovation 2012 award win...more
09/05/2012   Novozymes starts commercial supply of hyaluronic acid from Q7 cGMP facility...more
02/05/2012   Novozymes´ rAlbumin supports faster time to market for Neomend product...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code